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Abstract
Background: Menisci play a vital role in load transmission, shock absorption and joint stability. There is increasing
evidence suggesting that OA menisci may not merely be bystanders in the disease process of OA. This study
sought: 1) to determine the prevalence of meniscal degeneration in OA patients, and 2) to examine gene
expression in OA meniscal cells compared to normal meniscal cells.
Methods: Studies were approved by our human subjects Institutional Review Board. Menisci and articular cartilage
were collected during joint replacement surgery for OA patients and lower limb amputation surgery for
osteosarcoma patients (normal control specimens), and graded. Meniscal cells were prepared from these meniscal
tissues and expanded in monolayer culture. Differential gene expression in OA meniscal cells and normal meniscal
cells was examined using Affymetrix microarray and real time RT-PCR.
Results: The grades of meniscal degeneration correlated with the grades of articular cartilage degeneration (r =
0.672; P < 0.0001). Many of the genes classified in the biological processes of immune response, inflammatory
response, biomineral formation and cell proliferation, including major histocompatibility complex, class II, DP alpha
1( HLA-DPA1), integrin, beta 2 (ITGB2), ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), ankylosis,
progressive homolog (ANKH) and fibroblast growth factor 7 (FGF7), were expressed at significantly higher levels in
OA meniscal cells compared to normal meniscal cells. Importantly, many of the genes that have been shown to be
differentially expressed in other OA cell types/tissues, including ADAM metallopeptidase with thrombospondin type
1 motif 5 (ADAMTS5) and prostaglandin E synthase (PTGES), were found to be expressed at significantly higher
levels in OA meniscal cells. This consistency suggests that many of the genes detected in our study are disease-
specific.
Conclusion: Our findings suggest that OA is a whole joint disease. Meniscal cells may play an active role in the
development of OA. Investigation of the gene expression profiles of OA meniscal cells may reveal new therapeutic
targets for OA therapy and also may uncover novel disease markers for early diagnosis of OA.
Background
Osteoarthritis (OA) is a disease characterized by the
breakdown of articular cartilage and the formation of
osteophytes. However, it has been gradually realized that
OA is not merely an articular cartilage disease, but a
disease of the whole joint [1,2]. OA synovial membrane
and subchondral bone have drawn considerably atten-
tion recently. Aberrant gene expression in OA syno-
vium, OA fibroblast-like synoviocytes (FLS) and OA
subchondral bone has been detected [3-6]. These find-
ings suggest that OA synoviocytes and subchondral
bone cells may be involved in the disease process of OA.
Few studies have investigated the potential role of OA
meniscal cells in the disease process of OA. The knee
menisci are specialized tissues that play a vital role in
load transmission, shock absorption and joint stability.
Knee menisci may absorb most of the shock generated
at the joint because their combined mass is greater than
that of the articular cartilage. The current dogma is that
menisci protect the articular cartilage, but play a mini-
mal role in the disease process of OA unless they are
injured. However, increasing evidence suggests that knee
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process of OA. It has been reported that meniscal
degeneration is a feature of OA knee joints as revealed
by magnetic resonance imaging [7,8]. There is a strong
association between meniscal damage/degenerative tears
and cartilage loss [9]. In addition, it has been found that
meniscal degeneration contributes to joint space nar-
rowing [10]. Taken together, these findings and observa-
tions suggest that pathological changes and extracellular
matrix degeneration also occur in OA menisci. OA
menisci, similar to OA synovial membrane and OA sub-
chondral bone, may play an active role in the disease
process of OA.
In the present study, we examined the prevalence of
meniscal degeneration in OA patients who underwent
joint replacement surgery, and analyzed the correlation
between the degeneration of menisci and the degenera-
tion of articular cartilage. We also examined differential
gene expression between OA meniscal cells and normal
meniscal cells to test the hypothesis that OA meniscal
cells are different from normal meniscal cells and may
display a disease-specific gene expression profile. The
determination of the differential gene expression
between OA and normal meniscal cells may not only
provide experimental evident to support our hypothesis,
but also may reveal new therapeutic targets for OA
therapy and uncover novel disease markers for early
diagnosis of OA.
Methods
Menisci and articular cartilage specimens
Menisci and articular cartilage specimens were collected
from OA patients who underwent joint replacement
surgery and from osteosarcoma patients who underwent
lower limb amputation surgery with the approval of the
authors’ Institutional Review Board. The need for
informed consent was waived since the menisci and
articular cartilage were surgical waste of routine joint
replacement surgery and lower limb amputation surgery,
and there was no patient private information being col-
lected. Specimens were transported to the laboratory
from the operation room at our hospital in sterile tissue
culture medium. The medial menisci and the medial
articular cartilage of the tibia were graded (by DRM,
PRH and YS) according to following scales. For the
medial meniscus: 0 = normal appearing surface; 1 =
minimal fibrillation and degeneration; 2 = moderate
fibrillation and degeneration; 3 = severe fibrillation and
degeneration, no tears; 4 = severe fibrillation and degen-
eration, multiple incomplete tears, or complete tears.
For medial articular cartilage of the tibia: 0 = normal-
appearing surface; 1 = minimal fibrillation and degen-
eration; 2 = erosion extending to middle layers; 3 = ero-
sion extending into the deep layers; 4 = erosion
extending to the subchondral bone, and 5 = the majority
of articular cartilage completely absent.
Preparation and culture of meniscal cells
Dulbecco’s modified eagle medium, fetal bovine serum,
stock antibiotic and antimycotic mixture were products
of Invitrogen (Carlsbad, CA). Meniscal cells were iso-
lated from meniscal specimens as previously described
[11]. Briefly, when meniscal specimens were arrived in
sterile tissue culture medium, the central region of the
medial meniscus was incised, and processed to remove
fatty and synovial tissues. These meniscal specimens
were then minced into small pieces (3 mm × 3 mm),
and cultured in 100 mm plates at 37°C in medium con-
taining 0.5% antibiotic/antimycotic solution and 10%
serum. Every three days, medium was changed. Meniscal
cells proliferated, migrated out the tissues, attached to
the plate and expanded. When meniscal cells reached
80% confluence, they were replated and expanded in
monolayer culture. Passage two cells were used in all
studies. Meniscal cells prepared from meniscal speci-
mens derived from osteosarco m ap a t i e n t sw e r eu s e da s
normal control meniscal cells.
RNA extraction and microarrays
OA meniscal cells and normal meniscal cells (passage 2)
were plated in 100 mm plates at 75% confluence. On
the second day, medium containing 1% serum was
added and cells were cultured for twenty-four hours.
Medium (1% serum) was changed again and cells cul-
tured for another twenty-four hours. Total RNA was
extracted using Trizol reagent (Invitrogen, Carlsbad,
CA), and purified using Oligotex kit (Qiagen, Valencia,
CA). Microarray analyses were performed using these
RNA samples. For microarray analysis, double stranded
DNA was synthesized from RNA samples using Super-
Script double-stranded cDNA synthesis kit (Invitrogen,
Carlsbad, CA). The DNA product was purified using
GeneChip sample cleanup module (Affymetrix, Santa
Clara, CA). cRNA was synthesized and biotin labeled
using BioArray high yield RNA transcript labeling kit
(Enzo Life Sciences, Farmingdale, NY). The product was
purified using GeneChip sample cleanup module and
subsequently chemically fragmented. The fragmented,
biotinylated cRNA was hybridized to HG-U133_Plus_2
gene chip (Affymetrix, Santa Clara, CA) using Affyme-
trix Fluidics Station 400. The fluorescent signal was
quantified during two scans by Agilent Gene Array
Scanner G2500A (Agilent Technologies, Palo Alto, CA),
and GeneChip operating Software (Affymetrix, Santa
Clara, CA).
Real-time RT-PCR
cDNA was synthesized using TaqMan® Reverse Tran-
scription Reagents (Applied Biosystems, Inc., Univer-
sity Park, IL). Quantification of relative transcript
levels for selected genes and the housekeeping gene
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was performed using the ABI7000 Real Time PCR sys-
tem (Applied Biosystems, Inc., University Park, IL).
TaqMan® Gene Expression assays were used, which
contains a FAM-MGB probe for fluorescent detection.
cDNA samples were amplified with an initial Taq
DNA polymerase activation step at 95°C for 10 min-
utes, followed by 40 cycles of denaturation at 95°C for
15 seconds and annealing at 60°C for one minute. For
each gene, Ct values were obtained in triplicates. Fold
change was calculated [12] and the expression level of
the genes of interest was normalized to GAPDH.E a c h
real time RT-PCR experiment was repeated twice in
triplicate.
Statistical Analysis
The Spearman’s correlations between the grades of
meniscal degeneration and the grades of articular carti-
lage degeneration were calculated with SAS® software
(version 9.1). A two-tailed p-value of < 0.05 was consid-
ered statistically significant. For microarray analysis,
Genesifter software (VizX Labs, Seattle, WA) was used
to determine fold changes in gene expression, and gene
ontologies. Statistical significance was determined using
the Student t-test (p < 0.05). A correction factor for
false discovery rate was applied using the Benjamini and
Hochberg method [13].
Results
Degeneration of menisci in OA patients
Demographic patient features and assigned grades are
presented in Table 1. All menisci had signs of degenera-
tion. More than 80% menisci showed signs of severe
degeneration (grade 4 or grade 3). Representative images
of grade 4 OA menisci and grade 0 normal control
menisci are shown in Figure 1. Grade 4 OA menisci dis-
played discolorations and an extremely rough surface.
Severe degeneration and fissures/tears were apparent. In
contrast, grade 0 control menisci displayed a smooth,
white and glistening surface, with no any signs of
degeneration.
The relationship between the grade of menisci and the
grade of articular cartilage was examined. A correlation
between the grade of menisci and the grade of articular
cartilage was found. The Spearman’s correlation coeffi-
cient (r) was 0.672 (p < 0.0001). Of the seventeen OA
patients who had grade 5 (the highest grade of articular
cartilage degeneration) articular cartilage, fourteen
patients (82%) had grade 4 medial meniscus (the highest
grade of meniscal degeneration) and three patients had
grade 3 medial meniscus. Of the nineteen OA patients
who had grade 4 articular cartilages, ten patients had
grade 4 (58.82%) and seven had grade 3 (41.17%) medial
meniscus. Only two patients had grade 2 (0.11%) medial
meniscus.
Differential gene expression
Microarray analyses of the differential gene expression
between OA meniscal cells prepared from menisci
(grade 4) derived from five OA patients and normal
meniscal cells prepared from menisci (grade 0) derived
from three osteosarcoma patients were carried out as
described in Methods. The row microarray data can be
found in Gene Expression Omnibus (GEO; http://www.
ncbi.nlm.nih.gov/projects/geo/) with the accession
Table 1 Demographic data and grades of articular
cartilage and menisci*
I Cartilage Grade # Subjects Mean Age ± SD
01 F3 9
01 F1 2
01 M4 3
2 3 F, 1 M 62 ± 13
3 6 F, 5 M 64 ± 9
41 5 F , 4 M 6 2 ± 1 1
51 2 F , 5 M 6 7 ± 9
II Meniscus Grade # Subjects Mean Age ± SD
01 F3 9
01 F1 2
01 M4 3
2 4 F, 3 M 57 ± 12
31 2 F , 6 M 6 4 ± 9
42 0 F , 6 M 6 6 ± 9
*The first three patients are osteosarcoma patients. The rest fifty-one patients
are OA patients. F, female; M, male
Figure 1 Representative photos of normal control menisci and
OA menisci. Control menisci (left, top to bottom) were obtained
from a 39 year old female osteosarcoma patient, a 43 year old male
osteosarcoma patient and a 12 year old female osteosarcoma
patient underwent lower limb amputation surgery. OA menisci
(right, top to bottom) were obtained from a 65 year old female OA
patient, a 67 year old female OA patient and a 50 year old female
OA patient.
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data of the meniscal specimens which were the basis of
this analysis. Of more than 50,000 transcripts examined,
505 transcripts that displayed differential gene expres-
sion (more than 1.2 fold) were identified; 149 transcripts
were expressed at significantly higher levels and 356
transcripts at significantly lower levels in OA meniscal
cells compared to normal meniscal cells. The differen-
tially expressed genes were classified according to gene
ontology category biological process using GeneSifter
software (VizX Labs, Seattle, WA). Selected genes,
which fell into specific biological processes previously
implicated in OA or suspected to play a role in OA, or
displayed a distinct expression pattern, are listed in
Table 3.
We were particularly interested in identifying distinct
differential gene expression patterns. As shown in Table
3, distinct differential gene expression patterns were
apparent. For example, of the seven differentially-
expressed genes classified in the immune response bio-
logical process, five genes had elevated expressions but
only two genes had decreased expression in OA menis-
cal cells compared to the control meniscal cells. Of the
three differentially-expressed genes classified in the
inflammation response biological process, cytokine pro-
duction biological process, calcium ion transport biolo-
gical process or the biomineral formation biological
process, all these genes had elevated expression in OA
meniscal cells compared to the control meniscal cells.
Of the four differentially-expressed genes classified in
the regulation of phosphate metabolic process, three
genes had elevated expression but only one gene had
decreased expression in OA meniscal cells compared to
the control meniscal cells. Of the eighteen genes classi-
fied in the cell proliferation biological process, thirteen
genes had elevated expression but only five genes had
decreased expression in OA meniscal cells compared to
the control meniscal cells. Similar distinct expression
patterns were also found in other categories of biological
processes, including integrin-mediated signaling pathway
and skeletal system/tissue development biological pro-
cesses (Table 3).
In contrast, most of the genes with decreased expres-
sions in OA meniscal cells compared to the control
meniscal cells fell into a different set of biological pro-
cesses. For example, of the ten differentially-expressed
genes classified in the DNA repair biological process,
nine genes had decreased expression but only one gene
had elevated expression in OA meniscal cells compare
to the control meniscal cells. Of the ninety-one differen-
tially expressed genes classified in the cellular biosyn-
thetic process biological process, seventy-four genes had
decreased expression in OA meniscal cells and only
seventeen genes had elevated expression (Partial results
are listed in Table 3). These distinct distributions of the
differentially-expressed genes in different sets of biologi-
cal processes suggest that OA meniscal cells are differ-
ent from normal meniscal cells. We also analyzed the
differential gene expression between individual OA
m e n i s c a lc e l l s( O A 1 ,O A 2 ,O A 3 ,O A 4 ,a n dO A 5 )a n d
the normal control meniscal cells together as a control
group. Selected results are listed in Table 4.
Validation of differential expression of selected genes
The genes selected for validation by quantitative real-
time PCR included seven genes that displayed elevated
expression in OA meniscal cells compared to normal
meniscal cells (Table 5). They were major histocompat-
ibility complex, class II, DP alpha (HLA-DPA1), integrin,
beta 2 (ITGB2), ectonucleotide phosphodiesterase 1
(ENPP1), ADAM metallopeptidase with thrombospondin
t y p e1m o t i f5( ADAMTS5), prostaglandin E synthase
(PTGES), etc. Matrix metalloproteinase 10 (MMP10),
which displayed decreased expression in OA meniscal
cells compared to normal meniscal cells, was also
selected for validation. RNA sample extracted from OA1
meniscal cells (Table 4) and RNA sample (mixture)
extracted from the three normal control meniscal cells
were used in the quantitative real time RT-PCR experi-
ments. As shown in Table 5, the differential expressions
of these genes were confirmed.
Discussion
In the present study, we found that more than eighty
five percent (85.7%) of the OA patients who underwent
joint replacement surgery in our Medical Center had
severe degenerative menisci (grades 4 or 3), indicating
that meniscal degeneration is common in OA patients.
We also found that meniscal degeneration correlated
positively with articular cartilage degeneration in OA
patients. The Spearman’s correlation coefficient (r) was
0.672 (p < 0.0001). Our finding is consistent with pre-
vious reports that meniscal degeneration/tears is a fea-
ture of OA knee joints [7], that meniscal degeneration
contributes to joint space narrowing [10], that there is a
Table 2 Demographic data and grades of menisci that
were used to prepare meniscal cells*
Patients Age/Gender/Diagnosis Grade Meniscus
A 39/F (osteosarcoma) 0
B 43/M (osteosarcoma) 0
C 12/F (osteosarcoma) 0
1 65/F (OA patient) 4
2 56/F (OA patient) 4
3 50/F (OA patient) 4
4 52/F (OA patient) 4
5 61/M (OA patient) 4
* F, female; M, male; OA, osteoarthritis
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Biological process Gene
Name
Gene ID Differ
Exp
(fold)*
Description
Immune response
HLA-DPA1 M27487 5.3 Major histocompatibility complex, class II, DP alpha 1
IFI6 NM_022873 2.0 Interferon, alpha-inducible protein 6
CFH X04697 1.7 Complement factor H
CTSS NM_004079 1.6 Cathepsin S
FYN S74774 1.5 FYN oncogene related to SRC, FGR, YES
ILF2 NM_004515 -1.3 Interleukin enhancer binding factor 2, 45 kDa
PSMB9 AI375915 -1.2 Proteasome (prosome, macropain) subunit, beta type, 9
Inflammatory
Response
ITGB2 NM_000211 6.6 Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
CFH X04697 1.7 Complement factor H
BDKRB2 NM_000623 1.3 Bradykinin receptor B2
Cytokine production
SRGN NM_002727 2.8 Serglycin
ARNT AI768497 2.3 Aryl hydrocarbon receptor nuclear translocator
INHBA M13436 1.9 Inhibin, beta A
Calcium ion transport
CACNA1C F11066 1.5 Calcium channel, voltage-dependent, L type, alpha 1C subunit
FYN S74774 1.5 FYN oncogene related to SRC, FGR, YES
CHRNB2 NM_000748 1.4 Cholinergic receptor, nicotinic, beta 2 (neuronal)
Biomineral formation
ENPP1 BF057080 1.7 Ectonucleotide pyrophosphatase/phosphodiesterase 1
SRGN NM_002727 2.8 Serglycin
ACVR2A AI149508 1.5 Activin A receptor, type IIA
Cell proliferation
ITGB2 NM_000211 6.6 Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
FGF7 NM_002009 4.1 Fibroblast growth factor 7 (keratinocyte growth factor)
ELN AA479278 2.5 Elastin (supravalvular aortic stenosis, Williams-Beuren syndrome)
IGFBP7 NM_001553 2.4 Insulin-like growth factor binding protein 7
SKAP2 AB014486 2.2 Src kinase associated phosphoprotein 2
ARNT AI768497 2.3 Aryl hydrocarbon receptor nuclear translocator
FOXO1 NM_002015 1.5 Forkhead box O1
BCAT1 AL390172 1.5 Branched chain aminotransferase 1, cytosolic
ACVR2A AI149508 1.5 Activin A receptor, type IIA
TCF7L2 AA664011 1.4 Transcription factor 7-like 2 (T-cell specific, HMG-box)
CHRNB2 NM_000748 1.4 Cholinergic receptor, nicotinic, beta 2 (neuronal)
TCFL5 NM_006602 1.2 Transcription factor-like 5 (basic helix-loop-helix)
NRP1 AA609131 -1.3 Neuropilin 1
PHB AL560017 -1.3 Prohibitin
TBX5 NM_000192 -1.3 T-box 5
NCK2 BC000103 -1.2 NCK adaptor protein 2
PRPF19 NM_014502 -1.2 PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae)
Integrin-mediated signaling
pathway
ITGB2 NM_000211 6.6 Integrin, beta 2
ITGB8 BF513121 3.6 Integrin, beta 8
ITGA11 AF109681 1.5 integrin, alpha 11
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GAB2 NM_012296 1.5 GRB2-associated binding protein 2
Skeletal system/Tissue
development
DSP NM_004415 5.2 Desmoplakin
FGF7 NM_002009 4.2 Fibroblast growth factor 7 (keratinocyte growth factor)
SRGN NM_002727 2.8 Serglycin
INHBA M13436 1.9 Inhibin, beta A
TIMP3 AW338933 1.7 TIMP metallopeptidase inhibitor 3
ENPP1 BF057080 1.7 Ectonucleotide pyrophosphatase/phosphodiesterase 1
COL5A1 N30339 1.7 Collagen, type V, alpha 1
ACVR2A AI149508 1.5 Activin A receptor, type IIA
FBN1 AW955612 1.4 Fibrillin 1
BARX1 NM_021570N -1.9 BARX homeobox 1
GABBR1 NM_001470 -1.9 Gamma-aminobutyric acid (GABA) B receptor, 1
HOXA11 H94842 -1.5 Homeobox A11
CHST11 NM_018413 -1.5 Carbohydrate (chondroitin 4) sulfotransferase 11
NSDHL BC000245 -1.4 NAD(P) dependent steroid dehydrogenase-like
ZNRD1 AF230337 -1.3 Zinc ribbon domain containing 1
SMURF1 AF199364 -1.3 SMAD specific E3 ubiquitin protein ligase 1
DNA repair
ZSWIM7 BE645222 -1.6 Zinc finger, SWIM-type containing 7
WDR33 AB044749 -1.5 WD repeat domain 33
ASF1A NM_014034 -1.5 ASF1 anti-silencing function 1 homolog A (S. cerevisiae)
ATM U82828 -1.3 ataxia telangiectasia mutated
PMS2L1 AI375694 -1.3 Postmeiotic segregation increased 2-like 1
ALKBH2 AI865555 -1.2 AlkB, alkylation repair homolog 2 (E. coli)
XRCC6 NM_001469 -1.2 X-ray repair complementing defective repair in Chinese hamster cells 6
DCLRE1A D42045 -1.2 DNA cross-link repair 1A (PSO2 homolog, S. cerevisiae)
PRPF19 NM_014502 -1.2 PRP19/PSO4 pre-mRNA processing factor 19 homolog (S. cerevisiae)
ELN AA479278 2.5 Elastin (supravalvular aortic stenosis, Williams-Beuren syndrome)
Cellular biosynthetic process
PITX2 NM_000325 -6.4 Paired-like homeodomain 2
NR3C2 NM_000901 -5.8 Nuclear receptor subfamily 3, group C, member 2
GALNT6 AW014155 -4.5 Polypeptide N-acetylgalactosaminyltransferase 6
RGMB BE855765 -2.7 RGM domain family, member B
FOXF2 NM_001452 -2.2 Forkhead box F2
ZNF529 AL109722 -2.1 Zinc finger protein 529
BARX1 NM_021570 -1.9 BARX homeobox 1
DHODH M94065 -1.9 Dihydroorotate dehydrogenase
LMO4 BC003600 -1.8 LIM domain only 4
BRWD1 NM_018963 -1.7 Bromodomain and WD repeat domain containing 1
TARS2 NM_025150 -1.7 Threonyl-tRNA synthetase 2, mitochondrial (putative)
HLX M60721 -1.7 H2.0-like homeobox
BNC2 AI767962 -1.7 Basonuclin 2
PGD NM_002631 -1.6 Phosphogluconate dehydrogenase
MEIS1 AL832770 -1.6 Meis homeobox 1
ZNF420 AI339586 -1.6 Zinc finger protein 420
ZFP28 AA831323 -1.5 Zinc finger protein 28 homolog (mouse)
CARS2 NM_024537 -1.5 Cysteinyl-tRNA synthetase 2, mitochondrial (putative)
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lage loss [9], and that degenerative meniscal tears are
positively associated with the severity of articular degen-
eration compared with other types of meniscal tears
[14]. Taken together, our findings suggest that meniscal
degeneration in OA, similar to cartilage degeneration, is
a major degenerative process regardless of whether it is
primary or secondary. Further studies such as examina-
tion of the complete patient histories may provide infor-
mation regarding the cause-result relationship between
meniscal degeneration and cartilage degeneration.
If meniscal degeneration is a general feature of OA,
one would like to assess whether OA meniscal cells are
different from normal meniscal cells and may play a
role in the development of OA. To this end, we exam-
ined the differential gene expression between OA menis-
cal cells and normal control meniscal cells. We have
recently reported that numerous genes that were classi-
fied in the biological process of immune response dis-
played elevated expression in OA FLS compared to
rheumatoid arthritis (RA) FLS. HLA-DPA1 was
expressed in OA FLS (hTERT-OA 13A FLS) 16 fold
higher than that in RA FLS (hTERT-RA 516 FLS) [4].
Consistently, many genes that were classified in the bio-
logical process of immune response including HLA-
DPA1 also displayed elevated expression in OA meniscal
cells (Table 3). The findings indicate that OA meniscal
cells, similar to OA FLS, may be involved in the inflam-
matory process observed in OA.
Calcium-containing crystals are found in the joint
fluid of up to 65% of OA patients, and the presence of
these crystals correlates with the radiographic evidence
of cartilaginous degeneration [15-18]. There is evi-
dence indicating that crystals may promote joint
degeneration [19-21]. Most recently, it was demon-
strated that the inhibition of meniscal calcification by
calcium phosphocitrate, a potent anti-calcification
agent, was accompanied by a significant reduction in
the degeneration of articular cartilage in Hartley gui-
nea pigs [22]. These data suggest that excessive menis-
cal calcification may play a role in OA. However, there
have been no studies to investigate the alterations in
OA meniscal cells or to identify the candidate disease
genes that are potentially responsible for the excessive
meniscal calcification in OA. In the present study, we
found that many genes which are involved in biomin-
eral formation such as ENPP1 [23], in phosphate meta-
bolic process such as ITGB2 and in calcium ion
transport such as calcium channel, voltage-dependent,
L type, alpha 1C subunit (CACNA1C) are expressed at
an elevated levels in OA meniscal cells compared to
normal meniscal cells. These findings are consistent
Table 3: Genes differentially expressed in OA meniscal cells compared to normal meniscal cells. (Continued)
HOXA11 H94842 -1.5 Homeobox A11
PDLIM1 BC000915 13.2 PDZ and LIM domain 1 (elfin)
ITGB2 NM_000211 6.6 Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
LMCD1 NM_014583 3.5 LIM and cysteine-rich domains 1
KRT7 BC002700 3.1 Keratin 7
ARNT AI768497 2.3 Aryl hydrocarbon receptor nuclear translocator
ZNF415 NM_018355 2.2 Zinc finger protein 415
ZNF630 AK000580 2.0 Zinc finger protein 630
INHBA M13436 1.9 Inhibin, beta A
GALNT1 U41514 1.7 Polypeptide N-acetylgalactosaminyltransferase 1
ENPP1 BF057080 1.7 Ectonucleotide pyrophosphatase/phosphodiesterase 1
Miscellaneous
PTGES AF010316 3.2 Prostaglandin E synthase
ADAMTS5 NM_007038 1.7 ADAM metallopeptidase with thrombospondin type 1 motif, 5
(aggrecanase-2)
DSP NM_004415 5.2 Desmoplakin
FMOD NM_002023 2.7 Fibromodulin
sFRP4 AW089415 3.4 Secreted frizzled-related protein 4
MCAM M28882 2.3 Melanoma cell adhesion molecule
TNXB NM_004381 -1.3 Tenascin XB
FUS NM_004960 -1.5 Fusion (involved in t(12;16) in malignant liposarcoma)
TBX5 NM_000192 -1.3 T-box 5
*Positive number indicates elevated expression (fold) in OA meniscal cells compared to normal meniscal cells. Negative number indicates decreased expression
(fold) in OA meniscal cells compared to normal meniscal cells.
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more severe in OA menisci [24,25] and that calcium
content in OA menisci is positively correlated with the
stage of meniscal degeneration [26]. In addition to the
genes listed in Table 3, several other genes that have
been previously implicated in pathological calcification
were also detected (Table 4). They were ankylosis pro-
gressive homolog (ANKH)[ 2 7 , 2 8 ] ,m a t r i xG l ap r o t e i n
(MGP) [29,30] and tuftelin (TUFT1) [31-33]. Taken
together, our findings suggest that OA meniscal cells
may be actively involved in the meniscal calcification
process in OA.
Many genes that have been previously found to be
expressed at elevated levels in other types of OA cells or
tissues such as in OA articular cartilage and OA bone
were also detected in this study. They were integrin,
beta 8 (ITGB8) [34], insulin-like growth factor binding
protein 7 (IGFBP7) [34], fibromodul (FMOD)[ 2 8 ] ,
cathepsin S (CTSS) [35], secreted frizzled-related protein
4( SFRP4) [34], bone marrow stromal cell antigen 1
(BST1) [35], collagen, type XI, alpha 1 (COL11A1) [34],
collagen, type V, alpha 1 (COL5A1)[ 3 4 ] ,PTGES [36]
and ADAMTS5 [37]. These genes were expressed at sig-
nificantly elevated levels in OA meniscal cells compared
to normal meniscal cells (Tables 3 and 4). ADAMTS5 is
a major cartilage matrix degrading enzyme and has been
implicated in articular cartilage degeneration previously
[38,39]. The elevated expression of ADAMTS5 in OA
meniscal cells suggests that ADAMTS5 may play a role
in meniscal degeneration.
Table 5 Differential gene expression confirmed by real time RT-PCR*
Gene
name
Gene ID Differential Expression*
Microarray
Differential Expression* RT-
PCR
Description
HLA-DPA1 M27487 5.3 10.5 Major histocompatibility complex, class II, DP alpha
ITGB2 NM_000211 6.6 5.2 Integrin, beta 2
PTGES AF010316 3.2 3.4 Prostaglandin E synthase
ENPP1 BF057080 1.7 2.1 Ectonucleotide pyrophosphatase/phosphodiesterase 1
ADAMTS5 BI254089 1.7 1.9 ADAM metallopeptidase with thrombospondin type 1
motif, 5
IL26 NM_018402 1.7 4.3 Interleukin 26
TUFT1 NM_020127 2.8 3.9 Matrix metalloproteinase 1
MMP10 NM_002425 -2.7 -3.1 Matrix metalloproteinase 10
*Differential Expression – the numbers are the ratio of the relative expression level of a specific gene in OA1 meniscal cells to the relative expression level of the
specific gene in the control meniscal cells (mixture of RNA prepared from the three normal control meniscal cells).
Table 4 Genes differentially expressed in individual OA meniscal cells compared to normal meniscal cells.
Gene
Name
Gene ID OA1 OA1 OA3 OA4 OA5 Description
BST1 NM_004334 3.9 3.4 3.3 1.6 2.2 bone marrow stromal cell antigen 1
FGF9 NM_002010 3.7 2.4 3.7 2.5 2.9 Fibroblast growth factor 9
ACAN NM_013227 2.4 1.6 1.6 0.0 1.6 Aggrecan
COL11A1 J04177 0.0 11.5 5.8 2.2 3.6 Collagen, type XI, alpha 1
ANKH AL833238 0.0 1.8 1.7 1.5 1.8 Ankylosis, progressive homolog (mouse)
MGP NM_000900 11.8 4.7 21.6 0.0 17.6 Matrix Gla protein
TUFT1 NM_020127 2.8 2.7 1.9 0.0 0.0 Tuftelin 1
TFIP11 NM_012143 2.2 1.6 0.0 0.0 0.0 Tuftelin interacting protein 11
IL20RB AL578102 2.3 2.7 0.0 2.6 7.8 Interleukin 20 receptor beta
IL26 NM_018402 1.7 1.6 1.6 0.0 3.0 Interleukin 26
COL4A5 AW052179 -3.1 -3.0 -3.1 -3.0 -3.1 Collagen, type IV, alpha 5 (Alport syndrome)
MMP9 NM_004994 -2.2 -2.1 -2.1 0.0 -2.2 Matrix metallopeptidase 9
MMP10 NM_002425 -2.7 -2.6 -2.7 -1.5 -2.6 Matrix metallopeptidase 10
MMP12 NM_002426 -2.1 -2.0 -2.1 0.0 -2.1 Matrix metallopeptidase 12
FZD10 NM_007197 -1.6 -1.5 -1.6 -1.5 -1.5 Frizzled homolog 10 (Drosophila)
CYTL1 NM_018659 -2.6 -2.6 -2.6 -2.6 -2.5 Cytokine-like 1
CHODL NM_024944 -2.6 -2.6 -2.6 -2.6 Chondrolectin
*Positive number indicates elevated expression (fold) in OA meniscal cells compared to normal meniscal cells. Negative number indicates decreased expression
(fold) in OA meniscal cells compared to normal meniscal cells. 0.0 indicates there was no differential gene expression being detected.
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Page 8 of 10Furthermore, many genes that have been previously
found to be expressed at decreased levels in other types
of OA cells or tissues were also detected in this study.
They are MMP10 [34], MMP12 [40], tenascin XB
(TNXB) [34], fusion (FUS) [28], melanoma cell adhesion
molecule (MCAM) [35], and T-box 5 (TBX5)[ 5 ] .T h e s e
genes were expressed at decreased levels in OA meniscal
cells compared to normal meniscal cells (Tables 3 and
4). The consistency between our findings and the pre-
vious findings provides strong support for our hypoth-
esis that OA meniscal cells are different from normal
meniscal cells and may play an active role in the devel-
opment of OA.
Our study has some limitations which should be con-
sidered. The control meniscal cells we used were derived
from the menisci of osteosarcoma patients and were not
optimal normal control meniscal cells. To minimize this
limitation, we only collected overtly normal-appearing
meniscal and cartilage specimens (grade 0) from osteo-
sarcoma patients whose tumors were located far away
from the knee joints. In addition, we analyzed the differ-
ential gene expression using meniscal cells rather than
using meniscal tissue specimens directly to eliminate the
effect of different drugs that might be taken by OA and
osteosarcoma patients at the time of surgery.
Most meniscal cells synthesize type I collagen as their
major collagen product. The meniscal cells in the inner,
central nonvascularized region of meniscus synthesize
type II collagen. It is an open question at this time as to
whether a single cell type exists in the meniscus that
displays a fibroblast-like phenotype or a chondrocyte-
like phenotype depending on its environment, or
whether two or more distinct cell types exist. Therefore,
it is not absolutely certain at this time whether the dif-
ferences in the gene expressions detected in this study
reflect the overall differences between OA meniscal cells
and the control meniscal cells or only reflect the differ-
ences between a subpopulation of OA meniscal cells
and a subpopulation of the control meniscal cells.
Another limitation is that the age of osteosarcoma
patients was younger than the age of OA patients.
Therefore, certain genes we detected may be age-related
rather disease-specific. It is difficult to obtain age-
matched control meniscal specimens because osteosar-
coma occurs often in younger patients while OA occurs
mostly in older patients. We will continue this line of
study when more age matched normal control meniscal
specimens become available in the future. In spite of
these limitations, the consistency between our findings
and the previous findings that many of the genes we
detected are also abnormally expressed in other OA cell
types/tissues [4,5,23,28,34-36,40] suggests that many of
the differential gene expressions detected in this study
are disease-specific.
Conclusions
Our findings suggest that OA is not merely a cartilage
disease, but also a disease of the menisci. OA meniscal
cells may play an active role in the disease process of
OA. Investigation of the gene expression profile of OA
meniscal cells compared to normal meniscal cells may
reveal new therapeutic targets for OA therapy and
uncover novel disease markers for early diagnosis of OA.
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